Skip to main content

Advertisement

Table 28 Sensitivity analyses for smoking-adjusted data. Effect of removing relative risk/odds ratio estimates with largest Q2 values on heterogeneity and random-effects meta-analysis estimates

From: Systematic review of the relation between smokeless tobacco and cancer in Europe and North America

Cancer (number of estimates) RR/OR estimate removed   Heterogeneity Random-effects RR/OR (95% CI)
  Id. RR/OR Q2 χ2 P  
Oropharyngeal (n = 19)     69.5 < 0.001 1.36 (1.04–1.77)
  35 2.67 (1.83–3.90) 15.6 52.2 < 0.001 1.27 (0.99–1.64)
  13 2.05 (1.48–2.83) 12.2 37.9 0.002 1.20 (0.94–1.52)
  43 6.20 (1.90–19.80) 8.9 28.9 0.017 1.11 (0.90–1.38)
  7 0.70 (0.50–0.90) 6.2 21.0 0.101 1.17 (0.95–1.45)
Pancreatic (n = 7)     21.2 0.002 1.07 (0.71–1.60)
  5 1.67 (1.12–2.50) 6.0 13.8 0.017 0.95 (0.63–1.46)
  1 1.70 (0.90–3.10) 4.1 9.2 0.057 0.83 (0.54–1.28)
Overall digestive (n = 5)     17.3 0.002 0.86 (0.59–1.25)
  19 0.40 (0.24–0.69) 13.3 3.1 0.382 1.14 (0.99–1.33)
Lung (n = 6)     28.7 < 0.001 0.99 (0.71–1.37)
  6 1.77 (1.14–2.74) 15.5 12.7 0.013 0.83 (0.63–1.08)
  2 6.80 (1.60–28.5) 9.4 3.3 0.343 0.72 (0.65–0.80)
Bladder (n = 10)     22.3 0.008 0.95 (0.71–1.29)
  12 1.67 (1.09–2.55) 6.9 14.3 0.074 0.86 (0.65–1.13)
Non-Hodgkin's lymphoma (n = 3)       
     9.5 0.009 1.35 (0.62–2.95)
  19 4.00 (1.30–12.0) 6.9 2.2 0.137 0.92 (0.57–1.50)
Overall (n = 7)     27.1 < 0.001 0.98 (0.84–1.15)
  12 0.64 (0.53–0.78) 21.4 2.8 0.725 1.07 (1.00–1.15)
  1. CI = confidence interval; OR = odds ratio; RR = relative risk.